Diagnosis and Treatment > Medication

You are looking at 1 - 2 of 2 items for :

Clear All
Yasufumi Seki Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Yasufumi Seki in
Google Scholar
PubMed
Close
,
Satoshi Morimoto Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Satoshi Morimoto in
Google Scholar
PubMed
Close
,
Naohiro Yoshida Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Naohiro Yoshida in
Google Scholar
PubMed
Close
,
Kanako Bokuda Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Kanako Bokuda in
Google Scholar
PubMed
Close
,
Nobukazu Sasaki Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Nobukazu Sasaki in
Google Scholar
PubMed
Close
,
Midori Yatabe Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Midori Yatabe in
Google Scholar
PubMed
Close
,
Junichi Yatabe Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Junichi Yatabe in
Google Scholar
PubMed
Close
,
Daisuke Watanabe Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Daisuke Watanabe in
Google Scholar
PubMed
Close
,
Satoru Morita Departments of Diagnostic Imaging and Nuclear Medicine, Tokyo, Japan

Search for other papers by Satoru Morita in
Google Scholar
PubMed
Close
,
Keisuke Hata Departments of Urology, Kidney Center, Tokyo, Japan

Search for other papers by Keisuke Hata in
Google Scholar
PubMed
Close
,
Tomoko Yamamoto Departments of Surgical Pathology, Tokyo Women’s Medical University, Tokyo, Japan

Search for other papers by Tomoko Yamamoto in
Google Scholar
PubMed
Close
,
Yoji Nagashima Departments of Surgical Pathology, Tokyo Women’s Medical University, Tokyo, Japan

Search for other papers by Yoji Nagashima in
Google Scholar
PubMed
Close
, and
Atsuhiro Ichihara Departments of Endocrinology and Hypertension, Tokyo, Japan

Search for other papers by Atsuhiro Ichihara in
Google Scholar
PubMed
Close

Summary

Primary aldosteronism (PA) is more common than expected. Aberrant adrenal expression of luteinizing hormone (LH) receptor in patients with PA has been reported; however, its physiological role on the development of PA is still unknown. Herein, we report two unique cases of PA in patients with untreated Klinefelter’s syndrome, characterized as increased serum LH, suggesting a possible contribution of the syndrome to PA development. Case 1 was a 39-year-old man with obesity and hypertension since his 20s. His plasma aldosterone concentration (PAC) and renin activity (PRA) were 220 pg/mL and 0.4 ng/mL/h, respectively. He was diagnosed as having bilateral PA by confirmatory tests and adrenal venous sampling (AVS). Klinefelter’s syndrome was suspected as he showed gynecomastia and small testes, and it was confirmed on the basis of a low serum total testosterone level (57.3 ng/dL), high serum LH level (50.9 mIU/mL), and chromosome analysis. Case 2 was a 28-year-old man who had untreated Klinefelter’s syndrome diagnosed in his childhood and a 2-year history of hypertension and hypokalemia. PAC and PRA were 247 pg/mL and 0.3 ng/mL/h, respectively. He was diagnosed as having a 10 mm-sized aldosterone-producing adenoma (APA) by AVS. In the APA, immunohistochemical analysis showed co-expression of LH receptor and CYP11B2. Our cases of untreated Klinefelter’s syndrome complicated with PA suggest that increased serum LH levels and adipose tissues, caused by primary hypogonadism, could contribute to PA development. The possible complication of PA in hypertensive patients with Klinefelter’s syndrome should be carefully considered.

Learning points:

  • The pathogenesis of primary aldosteronism is still unclear.

  • Expression of luteinizing hormone receptor has been reported in aldosterone-producing adenoma.

  • Serum luteinizing hormone, which is increased in patients with Klinefelter’s syndrome, might contribute to the development of primary aldosteronism.

Open access
Ana Gonçalves Ferreira Endocrinology and Diabetes Department, Garcia de Orta Hospital, Almada, Portugal

Search for other papers by Ana Gonçalves Ferreira in
Google Scholar
PubMed
Close
,
Tiago Nunes da Silva Endocrinology Department, Portuguese Institute of Oncology Francisco Gentil, Lisbon, Portugal

Search for other papers by Tiago Nunes da Silva in
Google Scholar
PubMed
Close
,
Sofia Alegria Cardiology Department, Garcia de Orta Hospital, Almada, Portugal

Search for other papers by Sofia Alegria in
Google Scholar
PubMed
Close
,
Maria Carlos Cordeiro Endocrinology and Diabetes Department, Garcia de Orta Hospital, Almada, Portugal

Search for other papers by Maria Carlos Cordeiro in
Google Scholar
PubMed
Close
, and
Jorge Portugal Endocrinology and Diabetes Department, Garcia de Orta Hospital, Almada, Portugal

Search for other papers by Jorge Portugal in
Google Scholar
PubMed
Close

Summary

Pheochromocytoma/paraganglioma (PPGL) are neuroendocrine tumors that can secrete catecholamines. The authors describe a challenging case who presented as stress cardiomyopathy and myocardial infarction (MI). A 76-year-old man, with a medical history of Parkinson’s disease, type 2 diabetes mellitus, hypertension, dyslipidaemia and a previous inferior MI in 2001, presented to the emergency department due to chest pain, headaches and vomiting. He also reported worsening blood glucose levels and increasing constipation over the preceding weeks. BP was 185/89 mmHg (no other relevant findings). EKG had ST segment depression in leads V2-V6, T troponin was 600 ng/L (<14) and the echocardiogram showed left ventricular hypokinesia with mildly compromised systolic function. Nevertheless, he rapidly progressed to severe biventricular dysfunction. Coronary angiogram showed a 90% anterior descendent coronary artery occlusion (already present in 2001), which was treated with angioplasty/stenting. In the following days, a very labile BP profile and unexplained sinus tachycardia episodes were observed. Because of sustained severe constipation, the patient underwent an abdominal CT that revealed a retroperitoneal, heterogeneous, hypervascular mass on the right (62 × 35 mm), most likely a paraganglioma. Urinary metanephrines were increased several fold. 68Ga-DOTANOC PET-CT scan showed increased uptake in the abdominal mass (no evidence of disease elsewhere). He was started on a calcium-channel blocker and alpha blockade and underwent surgery with no major complications. Eight months after surgery, the patient has no evidence of disease. Genetic testing was negative for known germline mutations. This was a challenging diagnosis, but it was essential for adequate cardiovascular stabilization and to reduce further morbidity.

Learning points:

  • PPGL frequently produces catecholamines and can manifest with several cardiovascular syndromes, including stress cardiomyopathy and myocardial infarction.

  • Even in the presence of coronary artery disease (CAD), PPGL should be suspected if signs or symptoms attributed to catecholamine excess are present (in this case, high blood pressure, worsening hyperglycaemia and constipation).

  • Establishing the correct diagnosis is important for adequate treatment choice.

  • Inodilators and mechanical support might be preferable options (if available) for cardiovascular stabilization prior to alpha blockade and surgery.

  • Laboratory interference should be suspected irrespective of metanephrine levels, especially in the context of treated Parkinson’s disease.

Open access